Cyndeo Wealth Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-118,444
Closed -$3.72M – 568
2026
Q2
$3.72M Hold
118,444
– – 0.18% 129
2026
Q1
$2.93M Hold
118,444
– – 0.15% 142
2025
Q4
$2.76M Hold
118,444
– – 0.15% 137
2025
Q3
$2.33M Hold
118,444
– – 0.13% 153
2025
Q2
$2.57M Hold
118,444
– – 0.15% 148
2025
Q1
$2.87M Hold
118,444
– – 0.19% 132
2024
Q4
$2.47M Hold
118,444
– – 0.17% 144
2024
Q3
$2.35M Hold
118,444
– – 0.16% 149
2024
Q2
$1.83M Hold
118,444
– – 0.14% 165
2024
Q1
$1.89M Buy
118,444
+18,444
+18% +$278K 0.16% 157
2023
Q4
$1.68M Hold
100,000
– – 0.16% 155
2023
Q3
$1.17M Hold
100,000
– – 0.12% 163
2023
Q2
$1.34M Hold
100,000
– – 0.14% 152
2023
Q1
$1.66M Hold
100,000
– – 0.18% 141
2022
Q4
$1.86M Buy
+100,000
New +$1.54M 0.22% 129

Other funds holding CPRX

Cyndeo Wealth Partners's CPRX Position: Q3 2026 in Review

Cyndeo Wealth Partners sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 118,444 shares — an estimated $3.72M sold.

Cyndeo Wealth Partners first reported a position in CPRX in Q4 2022 and held it in 15 quarters. The position peaked at $3.72M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • Cyndeo Wealth Partners reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Cyndeo Wealth Partners sold 118,444 Catalyst Pharmaceutical shares in Q3 2026, an estimated $3.72M.
  • Cyndeo Wealth Partners first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 15 quarters.
  • Cyndeo Wealth Partners's Catalyst Pharmaceutical position peaked at $3.72M in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Cyndeo Wealth Partners's 13F filing for Q3 2026, filed 16 Oct 2026.